{"Title": "Treatment of Fabry's disease with the pharmacologic chaperone migalastat", "Year": 2016, "Source": "New Engl. J. Med.", "Volume": "375", "Issue": 6, "Art.No": null, "PageStart": 545, "PageEnd": 555, "CitedBy": 175, "DOI": "10.1056/NEJMoa1510198", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84981742779&origin=inward", "Abstract": "Copyright \u00a9 2016 Massachusetts Medical Society.BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal \u03b1-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of \u03b1-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant \u03b1-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant \u03b1-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (\u226550% reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant \u03b1-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant \u03b1-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30\u00b10.66 and -1.51\u00b11.33 ml per minute per 1.73 m2 of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant \u03b1-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group.", "AuthorKeywords": null, "IndexKeywords": ["1-Deoxynojirimycin", "Adolescent", "Adult", "Aged", "alpha-Galactosidase", "Diarrhea", "Double-Blind Method", "Fabry Disease", "Female", "Glomerular Filtration Rate", "Heart Ventricles", "Humans", "Hypertrophy, Left Ventricular", "Kidney", "Male", "Middle Aged", "Mutation", "Trihexosylceramides", "Young Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84981742779", "SubjectAreas": [["Medicine (all)", "MEDI", "2700"]], "AuthorData": {"7006706457": {"Name": "Germain D.P.", "AuthorID": "7006706457", "AffiliationID": "60021567", "AffiliationName": "Assistance Publique-H\u00f4pitaux de Paris"}, "55186237200": {"Name": "Hughes D.A.", "AuthorID": "55186237200", "AffiliationID": "60029950", "AffiliationName": "Department of Academic Haematology, Royal Free and University College Medical School"}, "57190338279": {"Name": "Jovanovic A.", "AuthorID": "57190338279", "AffiliationID": "60008873", "AffiliationName": "Salford Royal NHS Foundation Trust"}, "55399048700": {"Name": "Waldek S.", "AuthorID": "55399048700", "AffiliationID": "60032789", "AffiliationName": "University of Sunderland"}, "7006627484": {"Name": "Nicholls K.", "AuthorID": "7006627484", "AffiliationID": "60005245", "AffiliationName": "Department of Nephrology, Royal Melbourne Hospital"}, "25225283300": {"Name": "Bratkovic D.", "AuthorID": "25225283300", "AffiliationID": "60015153", "AffiliationName": "Metabolic Clinic, Women's and Children's Hospital"}, "7005292729": {"Name": "Bichet D.G.", "AuthorID": "7005292729", "AffiliationID": "60031078", "AffiliationName": "Clinical Research Division, H\u00f4pital du Sacr\u00e9-Coeur"}, "7005600401": {"Name": "Giugliani R.", "AuthorID": "7005600401", "AffiliationID": "60014120", "AffiliationName": "Medical Genetics Service, Clinic Hospital of Porto Alegre"}, "22934659700": {"Name": "Lourenco C.M.", "AuthorID": "22934659700", "AffiliationID": "60008088", "AffiliationName": "Hospital Das Cl\u00ednicas Faculdade de Medicina Da Universidade de S\u00e3o Paulo-Ribeir\u00e3o Preto"}, "35392413900": {"Name": "Wilcox W.R.", "AuthorID": "35392413900", "AffiliationID": "60002339", "AffiliationName": "Department of Human Genetics, Emory University School of Medicine"}, "14056992600": {"Name": "Shankar S.P.", "AuthorID": "14056992600", "AffiliationID": "60002339", "AffiliationName": "Department of Ophthalmology, Emory University School of Medicine"}, "55332852500": {"Name": "Feliciani C.", "AuthorID": "55332852500", "AffiliationID": "60004969", "AffiliationName": "Dermatology Unit, University of Parma"}, "56510123000": {"Name": "Ezgu F.", "AuthorID": "56510123000", "AffiliationID": "60013849", "AffiliationName": "Faculty of Medicine, Department and Laboratory of Pediatric Metabolic Disorders, Gazi University"}, "15051658100": {"Name": "Amartino H.", "AuthorID": "15051658100", "AffiliationID": "60007476", "AffiliationName": "Department of Pediatrics, Hospital Alem\u00e1n"}, "7005437081": {"Name": "Feldt-Rasmussen U.", "AuthorID": "7005437081", "AffiliationID": "60006564, 60015199", "AffiliationName": "Department of Medical Endocrinology, Rigshospital, Copenhagen University Hospital"}, "56490970000": {"Name": "Nedd K.", "AuthorID": "56490970000", "AffiliationID": "114912364", "AffiliationName": "Infusion Associates"}, "36180218300": {"Name": "Sharaf El Din U.", "AuthorID": "36180218300", "AffiliationID": "60024697", "AffiliationName": "Faculty of Medicine, Kasr El Ainy Hospital"}, "6602728134": {"Name": "Banikazemi M.", "AuthorID": "6602728134", "AffiliationID": "60018043", "AffiliationName": "New York Presbyterian Hospital"}, "7004262624": {"Name": "Charrow J.", "AuthorID": "7004262624", "AffiliationID": "60013227", "AffiliationName": "Division of Genetics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine"}, "6603894110": {"Name": "Dasouki M.", "AuthorID": "6603894110", "AffiliationID": "60007828", "AffiliationName": "Department of Urology, University of Kansas Medical Center"}, "55237052900": {"Name": "Tuffaha A.", "AuthorID": "55237052900", "AffiliationID": "60007828", "AffiliationName": "Department of Urology, University of Kansas Medical Center"}, "7005297499": {"Name": "Finegold D.", "AuthorID": "7005297499", "AffiliationID": "60005708", "AffiliationName": "Children's Hospital of Pittsburgh"}, "7007060971": {"Name": "Giraldo P.", "AuthorID": "7007060971", "AffiliationID": "60022336", "AffiliationName": "Hospital Miguel Servet"}, "7005575534": {"Name": "Torra R.", "AuthorID": "7005575534", "AffiliationID": "60023020, 60015559", "AffiliationName": "Fundacio Puigvert, Universidad Aut\u00f3noma de Barcelona"}, "6507595392": {"Name": "Goker-Alpan O.", "AuthorID": "6507595392", "AffiliationID": null, "AffiliationName": "O and O Alpan"}, "7004663930": {"Name": "Longo N.", "AuthorID": "7004663930", "AffiliationID": "60031018", "AffiliationName": "Department of Pediatric Genetics, University of Utah Hospitals and Clinics"}, "57190804228": {"Name": "Scott C.R.", "AuthorID": "57190804228", "AffiliationID": "60015481", "AffiliationName": "Department of Pediatrics, University of Washington"}, "7005128269": {"Name": "Packman S.", "AuthorID": "7005128269", "AffiliationID": "60023691", "AffiliationName": "Division of Pediatrics, University of California, San Francisco"}, "7006001698": {"Name": "Schiffmann R.", "AuthorID": "7006001698", "AffiliationID": "60031742, 60017310", "AffiliationName": "Institute of Metabolic Disease, Baylor Research Institute"}, "7801401265": {"Name": "Ludington E.", "AuthorID": "7801401265", "AffiliationID": null, "AffiliationName": "Agility Clinical"}, "15728320900": {"Name": "Lockhart D.J.", "AuthorID": "15728320900", "AffiliationID": null, "AffiliationName": "TranscripTx"}, "57201233304": {"Name": "Barlow C.", "AuthorID": "57201233304", "AffiliationID": "60028901", "AffiliationName": "Parkinson's Institute and Clinical Center"}, "57190621097": {"Name": "Viereck C.", "AuthorID": "57190621097", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57190620553": {"Name": "Kirk J.", "AuthorID": "57190620553", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57190620848": {"Name": "Yu J.", "AuthorID": "57190620848", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "8325555900": {"Name": "Benjamin E.R.", "AuthorID": "8325555900", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57197125561": {"Name": "Johnson F.", "AuthorID": "57197125561", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57196346215": {"Name": "Skuban N.", "AuthorID": "57196346215", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "55304953200": {"Name": "Castelli J.", "AuthorID": "55304953200", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57210542041": {"Name": "Barth J.", "AuthorID": "57210542041", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}}}